%0 Journal Article
%T ARID1A mutations in lung cancer: biology, prognostic role, and therapeutic implications.
%A Jin F
%A Yang Z
%A Shao J
%A Tao J
%A Reißfelder C
%A Loges S
%A Zhu L
%A Schölch S
%J Trends Mol Med
%V 29
%N 8
%D 2023 Aug 11
%M 37179132
%F 15.272
%R 10.1016/j.molmed.2023.04.005
%X Mutations in the AT-interacting domain-rich protein 1A (ARID1A) gene, a critical component of the switch/sucrose nonfermentable (SWI/SNF) complex, are frequently found in most human cancers. Approximately 5-10% of lung cancers carry ARID1A mutations. ARID1A loss in lung cancer correlates with clinicopathological features and poor prognosis. Co-mutation of ARID1A and epidermal growth factor receptor (EGFR) results in the limited efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs) but increases the clinical benefit of immune checkpoint inhibitors (ICIs). ARID1A gene mutation plays a role in cell cycle regulation, metabolic reprogramming, and epithelial-mesenchymal transition. We present the first comprehensive review of the relationship between ARID1A gene mutations and lung cancer and discuss the potential of ARID1A as a new molecular target.